Iovance Biotherapeutics (IOVA) Operating Expenses (2010 - 2026)

Iovance Biotherapeutics (IOVA) has reported Operating Expenses for 16 consecutive years, with $152.5 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Operating Expenses fell 10.6% year-over-year to $152.5 million; the TTM figure through Mar 2026 stood at $648.8 million (up 6.11% YoY), while the FY2025 annual figure was $666.9 million, up 19.22% from the prior year.
• Operating Expenses declined to $152.5 million in Q1 2026 per IOVA's latest filing, from $160.2 million in the prior quarter.
• Across five years, Operating Expenses topped out at $173.7 million in Q2 2025 and bottomed at $91.7 million in Q1 2022.
• Historically, Operating Expenses has averaged $131.7 million across 5 years, with a median of $121.7 million in 2023.
• Annual changes were most pronounced in 2025 — Operating Expenses surged 44.0% — and 2026, when it declined 10.6%.
• Iovance Biotherapeutics' Operating Expenses stood at $107.0 million in 2022, then gained by 13.74% to $121.7 million in 2023, then soared by 31.65% to $160.3 million in 2024, then fell by 0.02% to $160.2 million in 2025, then slipped by 4.84% to $152.5 million in 2026.
• Business Quant data shows IOVA's Operating Expenses at $152.5 million in Q1 2026, $160.2 million in Q4 2025, and $162.4 million in Q3 2025.